Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Rituximab antibody was raised against f(ab)2 fragment of Rituximab.
Recognizes the idiotypic determinants expressed by the Rituximab humanised monoclonal antibody. Rituximab is a therapeutic reagent directed against the human CD20 cell surface antigen. The antibody does not recognize other CD20 antibodies. The antibody has been used in ELISA assays to monitor the levels of Rituximab in patient serum following therapy. Has been used to detect Rituximab bound to the surface of the Raji B cell line, however detection of Rituximab bound 'in vivo' to B-CLL cells has not been demonstrated. It is possible that complement deposition on Rituximab opsonized cells inhibits binding of the anti-Rituximab antibody to cell bound Rituximab.
ELISA: Use as coating antibody.
Tris buffered saline, 0.09% sodium azide
+4°C or -20°C, Avoid repeated freezing and thawing.
Detection of Rituximab spiked into 10% human serum by sandwich ELISA. Human anti-Rituximab (HCA186) was used as the coating antibody and detection was performed by adding HRP conjugated anti-Rituximab antibody. Data are shown as the mean of three independent measurements
Requested From: United States
Date Requested: 2/22/2017